1. Home
  2. WOLF vs BNTC Comparison

WOLF vs BNTC Comparison

Compare WOLF & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$17.01

Market Cap

505.2M

Sector

Technology

ML Signal

HOLD

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

HOLD

Current Price

$11.55

Market Cap

411.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
BNTC
Founded
1987
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
505.2M
411.4M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
WOLF
BNTC
Price
$17.01
$11.55
Analyst Decision
Hold
Strong Buy
Analyst Count
5
3
Target Price
$12.75
$27.67
AVG Volume (30 Days)
1.3M
177.5K
Earning Date
05-07-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.94
EPS
N/A
N/A
Revenue
$1,385,982,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$0.39
$9.85
52 Week High
$36.60
$17.15

Technical Indicators

Market Signals
Indicator
WOLF
BNTC
Relative Strength Index (RSI) 45.44 49.32
Support Level $16.64 $11.30
Resistance Level $22.59 $13.06
Average True Range (ATR) 1.62 0.77
MACD -0.18 0.06
Stochastic Oscillator 22.06 41.02

Price Performance

Historical Comparison
WOLF
BNTC

About WOLF Wolfspeed Inc.

Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Share on Social Networks: